Stent implantation for May–Thurner syndrome with acute deep venous thrombosis: acute and long-term results from the ATOMIC (AcTive stenting for May–Thurner Iliac Compression syndrome) registry

2018 ◽  
Vol 34 (2) ◽  
pp. 131-138 ◽  
Author(s):  
Atsushi Funatsu ◽  
Hitoshi Anzai ◽  
Kota Komiyama ◽  
Kuniomi Oi ◽  
Hiroshi Araki ◽  
...  
2010 ◽  
Vol 40 (1) ◽  
pp. 134-138 ◽  
Author(s):  
C. Lindow ◽  
A. Mumme ◽  
G. Asciutto ◽  
B. Strohmann ◽  
T. Hummel ◽  
...  

2000 ◽  
Vol 36 (4) ◽  
pp. 1336-1343 ◽  
Author(s):  
Johannes Schweizer ◽  
Wilhelm Kirch ◽  
Rainer Koch ◽  
Holger Elix ◽  
Grit Hellner ◽  
...  

2012 ◽  
Vol 27 (1_suppl) ◽  
pp. 95-102 ◽  
Author(s):  
A J Comerota

This manuscript addresses six major issues involving deep venous thrombosis (DVT) and post-thrombotic syndrome. Prevention will likely see modest advances in pharmacological therapy mainly by extending prophylaxis in high-risk patients. More notable advances will be observed in mechanical means of prophylaxis, focusing on sustained application of devices that can move larger volumes of blood. Silent, large-vein thrombi continue to place patients at risk for fatal pulmonary embolism. Improved imaging techniques will permit us to identify these patients over the next eight years. In many of those patients, vena caval interruption will be required. Elimination of high-risk filters and the production of improved filters placed through low-profile systems with antithrombotic agents bound to their surface will improve the short- and long-term results for inferior vena cava filters. The long-term management of DVT will focus on establishing appropriate duration for the individual patient and will see the evolution towards direct Xa and Ha inhibitors. Patients with extensive DVT will more commonly receive treatment strategies designed to eliminate thrombus and restore patency. This will substantially reduce post-thrombotic morbidity and reduce recurrence. Post-thrombotic syndrome will see greater attention towards treating the intraluminal fibrosis, thereby eliminating post-thrombotic venous obstruction. Unfortunately, neovalves will still be searching for the appropriate application.


2010 ◽  
Vol 52 (1) ◽  
pp. 256
Author(s):  
C. Lindow ◽  
A. Mumme ◽  
G. Asciutto ◽  
B. Strohmann ◽  
T. Hummel ◽  
...  

2006 ◽  
Vol 7 (2) ◽  
pp. 106
Author(s):  
H.M. Dubé ◽  
B Cryer ◽  
A.G. Clifford ◽  
C.M. Barry ◽  
L.B. Schwartz

2010 ◽  
Vol 55 (10) ◽  
pp. A193.E1808
Author(s):  
Christopher Lichtenwalter ◽  
James A. de Lemos ◽  
Owen Obel ◽  
Abdul-rahman Riyad Abdel-karim ◽  
Michele Roesle ◽  
...  

2008 ◽  
Vol 136 (3-4) ◽  
pp. 181-186 ◽  
Author(s):  
Djordje Radak ◽  
Lazar Davidovic

Procedures used in treatment of carotid stenosis are endarterectomy, PTA with stent implantation, resection with graft interposition and by-pass procedure. Segmental lesions are found more often and treated by the first two mentioned procedures. In case of longer lesions and extension to the greater part of the common carotid artery, the other two procedures are performed. For the past few years, the main dilemma has been whether to perform carotid endarterectomy or PTA with stent implantation. Both early and long-term results speak in favour of carotid endarterectomy, regardless of an increased number of PTA and carotid stenting. At the same time, PTA and carotid stenting are more expensive procedures. Both methods have their defined and important roles in treatment of segmental occlusive carotid lesions. Severe cardiac, pulmonary and renal conditions, which increase the risk of general anaesthesia, are not an absolute indication for PTA and stenting, since endarterectomy can be done in regional anaesthesia. Main indications for PTA with stent implantation are: surgically inaccessible lesions (at or above C2; or subclavian); radiation- induced carotid stenosis; prior ipsilateral radical neck dissection; prior carotid endarterectomy (restenosis).


Blood ◽  
2001 ◽  
Vol 98 (6) ◽  
pp. 1727-1731 ◽  
Author(s):  
Janna M. Journeycake ◽  
Charles T. Quinn ◽  
Kim L. Miller ◽  
Joy L. Zajac ◽  
George R. Buchanan

Abstract Central venous catheters (CVCs) are a common adjunct to hemophilia therapy, but the risk of CVC-related deep venous thrombosis (DVT) in hemophiliacs is not well defined. In a previous study, 13 patients with CVCs had no radiographic evidence of DVT. However, recent abstracts and case studies demonstrate that DVT does occur. Therefore, this study sought to determine the frequency of DVT in children with hemophilia and long-term CVCs and to correlate venographic findings with clinical features. All hemophilia patients with tunneled subclavian CVCs in place for 12 months or more were candidates for evaluation. Patients were examined for physical signs of DVT and questioned about catheter dysfunction. Contrast venograms were obtained to identify DVT. Fifteen boys with severe hemophilia were evaluated, including 9 from the initially studied group of 13. Eight patients had evidence of DVT, 5 of whom previously had normal venograms. Five of 15 patients had clinical problems related to the CVC, all of whom had DVT. Four of 15 patients had suggestive physical signs; 3 had DVT. The mean duration of catheter placement for all patients was 57.5 months (range, 12-102 months). For patients with DVT, the mean duration was 66.6 ± 7.5 months, compared to 49.5 ± 7.2 months for patients without DVT (P = .06). No patient whose CVC was in place fewer than 48 months had an abnormal venogram. Many hemophilia patients with CVCs develop DVT of the upper venous system, and the risk increases with duration of catheter placement.


Sign in / Sign up

Export Citation Format

Share Document